EQS-News: Immunic, Inc.: Immunic Announces Positive Results

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human

Related Keywords

Australia , New Zealand , Russia , Ukraine , Edna Kaplan , Paula Schwartz , Jessica Breu , Daiichi Sankyo , Andreas Muehler , Daniel Vitt , Exchange Commission , Daiichi Sankyo Co Ltd , Rx Communications Group , Nasdaq , Immunic Inc , Distribution Services , Announces Positive Results , Multiple Ascending Dose Parts , Its Phase , Healthy Human Subjects , Healthy Human , Data Revealed , Favorable Safety , Pharmacokinetic Profile , Day Multiple Dosing , Maximum Tolerated Dose Reached , Investigated Doses Expected , Exceed Required Therapeutic Dosing , Celiac Disease Ongoing , Held Today , Investigational Medicinal Product , Chief Medical Officer , Chief Executive Officer , Eastern Time , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Corporate News , Regulatory Announcements , News , Immunic , Nnounces , Positive , Results , Rom , Single , Multiple , Ascending , Nose , Parts , Hase , Linical , Trial , Healthy , Human , Subjects ,